FeesSafety
Pluang+

Aclaris' Phase 2 trial of bosakitug for atopic dermatitis fails primary endpoint but shows immune biomarker effects.

Company Fundamentals
16 Nov 2026, 10:28 WIB
GlobeNewsWire
View Source
Bearish
Aclaris' Phase 2 trial of bosakitug for atopic dermatitis fails primary endpoint but shows immune biomarker effects.

Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug (ATI-045), an anti-TSLP antibody for moderate-to-severe atopic dermatitis, did not meet its primary or secondary endpoints. Despite this, the drug showed strong target engagement and reduced immune activation biomarkers, and was well tolerated. Aclaris will continue focusing on other drug candidates, including oral kinase inhibitors and a bispecific antibody ATI-052, with several Phase 2b trials and regulatory milestones planned for 2027.

Aclaris Therapeutics' Phase 2 results for bosakitug in atopic dermatitis provide context for readers. For those tracking health-sector stocks, 60 of 150 US stocks rose while 86 fell on Pluang. Notable movers include Summit Therapeutics Inc (SMMT) down 19.93% at USD 11.33, Aveanna Healthcare Holdings Inc (AVAH) down 12.15% at USD 11.50, and Citius Pharmaceuticals Inc (CTXR) up 11.34% at USD 0.54. Data is as of Nov 16, 2026 15:41 WIB.

More News

Danske Bank buys back 25,000 shares in week 46, continuing its DKK 4.5 billion buy-back program.

Danske Bank buys back 25,000 shares in week 46, continuing its DKK 4.5 billion buy-back program.

Danske Bank executed transactions to repurchase 25,000 shares during week 46 as part of its ongoing share buy-back program announced in February 2026. The program targets a total buy-back of up to DKK 4.5 billion or 45 million shares by January 2027....

Company Fundamentals
Neutral
1 hour ago
French firms boost AI-driven cybersecurity, focusing on productivity and operational results over processes.

French firms boost AI-driven cybersecurity, focusing on productivity and operational results over processes.

A new study by Securonix shows French organizations are increasingly adopting AI-driven cybersecurity operations, prioritizing productivity and measurable outcomes rather than just processes. French firms lead in allowing AI to automatically trigger ...

Market News
Neutral
2 hours ago
Lakefront Biotherapeutics launches new €50M share buyback after completing initial program

Lakefront Biotherapeutics launches new €50M share buyback after completing initial program

Lakefront Biotherapeutics has started a new €50 million share buyback program following the completion of its initial €50 million program, in which it repurchased about 1.99 million shares. The new program, running until March 31, 2027, aims to enhan...

Company Fundamentals
Bullish
3 hours ago
Exosens wins order for 25,000 image intensifier tubes to boost European night vision tech.

Exosens wins order for 25,000 image intensifier tubes to boost European night vision tech.

Exosens secured a firm order to supply 25,000 high-performance 4G+ image intensifier tubes to Theon Sensors for integration into night vision devices, with deliveries starting late 2026. This order is part of a long-term agreement through 2030 and in...

Market News
Bullish
3 hours ago
Exosens secures a major order for 25,000 light intensifier tubes for night vision devices through 2030.

Exosens secures a major order for 25,000 light intensifier tubes for night vision devices through 2030.

Exosens has received a firm order for 25,000 high-performance 4G+ light intensifier tubes to equip night vision products for Theon, under a long-term supply agreement extended through 2030. The order includes options for an additional 35,000 tubes, p...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App